{"DataElement":{"publicId":"6384976","version":"3","preferredName":"Overall Lesion Response iRECIST Type","preferredDefinition":"Text term to represent the overall disease response in a target, non-target, or new lesion using the iRECIST criteria.","longName":"OVR_LES_RESP_iRECIST_TP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"2188872","version":"1","preferredName":"Overall Lesion Response","preferredDefinition":"Information relating to the overall lesion response.","longName":"OVERALL_LES_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206600","version":"1","preferredName":"Overall Lesion","preferredDefinition":"Including everything.:(LEE-zhun) An area of abnormal tissue change.","longName":"C25605:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FBC1-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E49C180D-8D57-0916-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"8/7/18 jk added irRECIST CSI.  8/30/17 tt transferred context, added registration status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5895897","version":"2","preferredName":"iRECIST Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities._iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. (Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152.)_Something distinguishable as an identifiable class based on common qualities.","longName":"IRECIST_TYPE","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-5933-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"iCPD","valueDescription":"Progressive Disease, Confirmed","ValueMeaning":{"publicId":"5895898","version":"1","preferredName":"Progressive Disease, Confirmed","longName":"5895898","preferredDefinition":"Having been established or verified.: A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-7116-75C8-E053-F662850AED93","latestVersionIndicator":"Yes","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"HARTLEYG","dateModified":"2018-04-24","changeDescription":"User curated long name to support DCI, Modified RANO, ghd, 04.24.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-593D-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"iUPD","valueDescription":"Unconfirmed Progressive Disease","ValueMeaning":{"publicId":"5895900","version":"1","preferredName":"Unconfirmed Progressive Disease","longName":"5895900","preferredDefinition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unconfirmed Progressive Disease","conceptCode":"C123607","definition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-713C-75C8-E053-F662850AED93","latestVersionIndicator":"Yes","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-5947-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"iSD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-5951-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"iPR","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3854969","version":"1","preferredName":"Partial Remission","longName":"3854969","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86B4-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-595B-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"iCR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3951936","version":"1","preferredName":"Complete Remission","longName":"3951936v1.00","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5DA-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SOKKERL","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-5965-2CB4-E053-F662850A74FA","beginDate":"2017-07-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"Not done","valueDescription":"Not Done","ValueMeaning":{"publicId":"3104692","version":"1","preferredName":"Not Done","longName":"3104692v1.00","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88084310-6796-6259-E040-BB89AD4311C3","latestVersionIndicator":"Yes","beginDate":"2010-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-02","modifiedBy":"RAGUNATHANU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0A34B5-5979-2CB4-E053-F662850A74FA","beginDate":"2019-07-19","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6819866","version":"1","preferredName":"Immune-Modified Response Evaluation Criteria in Solid Tumors Type","preferredDefinition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.:Something distinguishable as an identifiable class based on common qualities.","longName":"C136711:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Modified Response Evaluation Criteria in Solid Tumors","conceptCode":"C136711","definition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0A34B5-590C-2CB4-E053-F662850A74FA","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"iRECIST:  Immune Response Evaluation Criteria in Solid Tumours (RECIST)-2017","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"8E0A34B5-591D-2CB4-E053-F662850A74FA","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"KNABLEJ","dateModified":"2019-07-22","changeDescription":"7/22/19 jk released per DCI/Annie's review.  7/19/19 jk VD versioned to add PV \"Not done\", chg LN, increase max length.   10/22/18 tmt Transferred from DCI to NCI Standards context as part of RECIST FG content.  Changes should not be made to this VD without coordinating with DCI/Duke (Michael D. Leonard, Annie Tsui, Michael Goodin).Curated to support Immunotherapy Response Protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5635324","version":"1","longName":"RECIST","context":"NCI Standards"},{"publicId":"6006601","version":"1","longName":"iRECIST","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Overall response","type":"Preferred Question Text","description":"Overall response","url":null,"context":"NCI Standards"},{"name":"iRECIST","type":"Alternate Question Text","description":"Overall response","url":null,"context":"NCI Standards"}],"origin":"iRECIST:  Immune Response Evaluation Criteria in Solid Tumours (RECIST)-2017","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"8E0A3BE0-B7D3-1D63-E053-F662850AF0F4","latestVersionIndicator":"Yes","beginDate":"2018-10-22","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-19","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"7/22/19 jk released per DCI/Annie's review.   7/19/19 jk CDE versioned for new VD version due to max length increase, new PV (Not done) for DCI MEL_PPD1_101803 study.  10/22/18 jk versioned to chg SN from system-generated to text.  10/7/18 jk Released per Fall 2018 Content Team review.  8/7/18 jk created based on iRECIST guideline.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}